As Chief Scientific Officer and President of R&D at Pfizer, Dr. Dolsten led one of the world’s largest and most productive research organizations, achieving regulatory approval for more than 35 medicines and vaccines across oncology, immunology, cardiometabolic disease, rare disease, and infectious disease.
Dr. Dolsten advised Presidents Obama, Biden, and Trump on public health and pandemic response, including Operation Warp Speed and G7 advisory efforts, and has participated in large-scale mergers and acquisitions exceeding $200B in aggregate value.
Scientific leadership
GMD.BIO applies senior-level R&D leadership experience across drug discovery, development, regulatory approval, and portfolio strategy. Work spans small molecules, biologics, vaccines, and genetic medicines, informed by direct operational responsibility at global scale.
Applied artificial intelligence
Dr. Dolsten serves on the boards of and advises multiple AI-enabled biotechnology and TechBio companies, applying AI across antibody design, macrocyclic drug prediction, lab data capture, single-cell immunology, and scientific visualization. AI is used as a discovery and decision tool, not a marketing layer.
